Takaku et al.

U.S.S.N.: 10/549,601

C. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the

application:

1. (currently amended) An antisense oligonucleotide consisting of a nucleotide

sequence complementary to a nucleotide sequence consisting of at least 15 successive

nucleotides in the nucleotide sequence consisting of nucleotides 6-44 of SEQ ID NO: 1.

2. (currently amended) An antisense oligonucleotide comprising a nucleotide

sequence which specifically hybridizes to a nucleotide sequence consisting of at least 15

successive nucleotides in the nucleotide sequence consisting of nucleotides 6-44 of SEO ID NO:

1.

3. (previously presented) The oligonucleotide according to claim 1 wherein at least

one internucleotide bond is a phosphorothioate bond.

(currently amended) A pharmaceutical composition comprising the

oligonucleotide according to claim 1, and a pharmaceutically acceptable carrier or diluent.

(previously presented) An anti-HIV agent comprising the oligonucleotide

according to claim 1.

3

Takaku et al. U.S.S.N.: 10/549,601

 (currently amended) A pharmaceutical composition for treating or preventing HIV, comprising the oligonucleotide according to claim 1, and a pharmaceutically or veterinarily acceptable carrier or diluent.

7-8. (cancelled)

- (previously presented) The oligonucleotide according to claim 2, wherein at least one internucleotide bond is a phosphorothioate bond.
- (currently amended) A pharmaceutical composition comprising the
 oligonucleotide according to claim 2, and a pharmaceutically acceptable carrier or diluent.
- (currently amended) A pharmaceutical composition comprising the oligonucleotide according to claim 3, and a pharmaceutically acceptable carrier or diluent.
- (previously presented) An anti-HIV agent comprising the oligonucleotide according to claim 2.
- (previously presented) An anti-HIV agent comprising the oligonucleotide according to claim 3.

Takaku et al.

U.S.S.N.: 10/549,601

14. (currently amended) A pharmaceutical composition for treating or preventing

HIV, comprising the oligonucleotide according to claim 2, and a pharmaceutically acceptable

carrier or diluent.

15. (currently amended) A pharmaceutical composition for treating or preventing

HIV, comprising the oligonucleotide according to claim 3, and a pharmaceutically acceptable

carrier or diluent.

16-17. (canceled)

* * * * *